9781138288768 (hardcover) 1138288764 (hardcover) 9781315267692 (e-book)
Routledge-Cavendish research in intellectual property.
This book explores the current difficulties with pharmaceutical patents in the post-TRIPS era and suggests how working with international organizations may improve access to affordable medicines in developing countries. Patents, including pharmaceutical patents, enjoy extended protection for twenty years under the TRIPs Agreement. The Agreement has resulted in creating a two-tier system of the World Trade Organisation Member States, and its implementation has seen the price of pharmaceutical products skyrocket, putting essential medicines beyond the reach of the common man. The hardest hit populations come from the developing and least developed countries, which have either a weak healthcare system or no healthcare at all, where access to essential and affordable medicines is extremely difficult to achieve.
Bibliography, etc. Note
Includes bibliographical references and index.
Formatted Contents Note
Preface Introduction A jurisprudential enquiry into the justification of international IP rights protection, with particular reference to pharmaceutical patents Intellectual property in the multilateral trading system : forum shifting, TRIPS Agreement, Doha Declaration and TRIPS flexibilities Undermining TRIPS flexibilities : FTAs, RTAs, EPAs, TRIPS-plus and stoppage in transit Brazil : ambitious missions and early TRIPS implementation China : the uneasy transition India : the transition from process to product patent South Africa : against all odds Kenya : can generics still reach the needy? TRIPS Agreement and the future of acess to affordable medicines.
K1519.D78 S86 2018
Available in Other Form
Online version: Sundaram, Jae. Pharmaceutical patent protection and world trade law. New York : Routledge, 2018
Abingdon, Oxon ; New York, NY : Routledge, 2018.